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Postnatal Regulation of Bone Growth by Muscle IGF-1
Abstract
Interplay between muscle and bone is known to play an important role in growth modifications. Muscle
loading from muscle hypertrophy promotes adjacent bone growth via Insulin-like Growth Factor-1 (IGF-1).
Yet, in the absence of muscle hypertrophy, bone growth is not completely aborted indicating potential direct
muscle paracrine role of muscle IGF-1 on bone. Maximizing growth potential and enhancing bone growth in
mature bone in craniofacial skeleton is a significant benefit in orthodontic treatment. In this study, potential
anabolic effect of muscle IGF-1 on post-natal mandibular growth is investigated. Methods: Four wild-type
(WT) mice each at age of 6 weeks and 10 weeks; four dominant negative muscle specific IGF-1 receptor mice
(MKR) each at age of 6 weeks and 10 weeks with one side masseter muscles injected with AAV-IGF-1 at 2
week of age were utilized. Four WT female and four WT male at age of 26 weeks with AAV-IGF-1 injection at
age of 18 week were utilized. Muscle fiber size, mandibular bone lengths (sagittal and vertical) and condylar
growth plate were evaluated from each animal. Results: Supplemental IGF-1 increased vertical mandibular
bone growth in 6 weeks old MKR mice while 6 weeks old WT mice showed more increase in horizontal
mandibular bone growth. There was no significant difference in mandibular growth in 10 weeks old WT and
MKR mice. There was no significant effect of IGF-1 on muscle fiber size in both WT and MKR mice.
Condylar growth plate analysis showed more mature form of chondrocytes with IGF-1 supplement.








muscle IGF-1, bone growth, MKR, mandible, condyle growth, masseter
Subject Categories
Dentistry | Musculoskeletal, Neural, and Ocular Physiology | Musculoskeletal System | Oral Biology and Oral
Pathology | Orthodontics and Orthodontology




“POSTNATAL	  REGULATION	  OF	  BONE	  GROWTH	  BY	  MUCLE	  IGF-­‐1”	  
	  
	   	  by	  	  HyeYoon	  Helen	  Choi	  	  Elisabeth	  Barton	  	  	  	  	  	  	  	  	  	  	  Thesis	  Defense	  	  Master	  of	  Science	  in	  Oral	  Biology	  	  	  	  	  	  	  	  	  University	  of	  Pennsylvania	  School	  of	  Dental	  Medicine	  Department	  of	  Orthodontics
	   2	  
	  
Abstract	  
	  	   Interplay	   between	  muscle	   and	   bone	   is	   known	   to	   play	   an	   important	   role	   in	  growth	  modifications.	  Muscle	  loading	  from	  muscle	  hypertrophy	  promotes	  adjacent	  bone	  growth	  via	  Insulin-­‐like	  Growth	  Factor-­‐1	  (IGF-­‐1).	  Yet,	  in	  the	  absence	  of	  muscle	  hypertrophy,	   bone	   growth	   is	   not	   completely	   aborted	   indicating	   potential	   direct	  muscle	   paracrine	   role	   of	  muscle	   IGF-­‐1	   on	   bone.	  Maximizing	   growth	   potential	   and	  enhancing	   bone	   growth	   in	   mature	   bone	   in	   craniofacial	   skeleton	   is	   a	   significant	  benefit	   in	   orthodontic	   treatment.	   In	   this	   study,	   potential	   anabolic	   effect	   of	  muscle	  IGF-­‐1	   on	   post-­‐natal	   mandibular	   growth	   is	   investigated.	   Methods:	   Four	   wild-­‐type	  (WT)	  mice	   each	   at	   age	   of	   6	  weeks	   and	   10	  weeks;	   four	   dominant	   negative	  muscle	  specific	  IGF-­‐1	  receptor	  mice	  (MKR)	  each	  at	  age	  of	  6	  weeks	  and	  10	  weeks	  with	  one	  side	  masseter	  muscles	  injected	  with	  AAV-­‐IGF-­‐1	  at	  2	  week	  of	  age	  were	  utilized.	  Four	  WT	  female	  and	  four	  WT	  male	  at	  age	  of	  26	  weeks	  with	  AAV-­‐IGF-­‐1	  injection	  at	  age	  of	  18	   week	   were	   utilized.	   Muscle	   fiber	   size,	   mandibular	   bone	   lengths	   (sagittal	   and	  vertical)	   and	   condylar	   growth	   plate	   were	   evaluated	   from	   each	   animal.	   Results:	  Supplemental	  IGF-­‐1	  increased	  vertical	  mandibular	  bone	  growth	  in	  6	  weeks	  old	  MKR	  mice	  while	  6	  weeks	  old	  WT	  mice	  showed	  more	   increase	   in	  horizontal	  mandibular	  bone	  growth.	  There	  was	  no	  significant	  difference	  in	  mandibular	  growth	  in	  10	  weeks	  old	  WT	  and	  MKR	  mice.	  There	  was	  no	  significant	  effect	  of	  IGF-­‐1	  on	  muscle	  fiber	  size	  in	   both	  WT	   and	  MKR	  mice.	   Condylar	   growth	   plate	   analysis	   showed	  more	  mature	  form	  of	   chondrocytes	  with	   IGF-­‐1	   supplement.	  Conclusion:	  Post-­‐natal	  muscle	   IGF-­‐1	  promoted	  bone	  growth	  in	  the	  absence	  of	  muscle	  hypertrophy.	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Introduction	  	  There	  has	  been	  a	   long,	  yet	  continued	  study	  on	  muscle	  and	  underlying	  bone	  interactions.	  Muscle	  can	  influence	  bone	  in	  two	  general	  ways.	  First,	  changes	  in	  either	  mass	   or	   strength	   of	   muscle	   can	   affect	   bone	   growth	   mechanically	   through	   forces	  generated	  by	  muscle	  loading.	  Second,	  muscle	  is	  a	  source	  of	  local	  growth	  factors,	  like	  Insulin-­‐like	   Growth	   Factor-­‐1	   (IGF-­‐1)	   that	   act	   on	   bone	   and	   provide	   a	   chemical	  influence	  on	  bone	  growth.	  	  Since	  the	  functional	  matrix	  hypothesis	  postulated	  that	  epigenetic	  factors	  like	  skeletal	   muscle	   regulates	   skeletal	   tissue	   modifications	   (Moss,	   1968),	   Frost	  developed	  the	  mechanostat	  hypothesis,	  emphasizing	  that	  mechanical	  loads	  on	  bone	  largely	  determines	  bone	  physiology	  while	  non-­‐mechanical	  factors	  only	  account	  for	  a	  small	  part	  (Frost,	  1987).	  According	  to	  the	  hypothesis,	  when	  bone	  grows	  or	  muscle	  force	  increases,	  surrounding	  tissue	  is	  strained,	  and	  together	  with	  other	  signals	  and	  non-­‐mechanical	   factors,	   a	   regulatory	   feedback	   loop	   is	   established	   between	   the	  muscle	   strain	   and	   effector	   cells.	   Therefore,	   the	   mechanical	   strain	   dictates	   bone	  remodeling	  and	  strength	  while	  chemical	  agents	   like	  hormones	  are	   just	  modulators	  (Schoenau,	   2005).	   Supporting	   the	   idea,	   Duchenne	   muscular	   dystrophy	   (DMD)	  patients	  who	  inherently	  have	  weaker	  muscle	  show	  decreased	  bone	  mineral	  density	  and	   small	   bones	   in	   comparison	   to	   aged	   matched	   healthy	   people	   (Bianch,	   2003),	  (King,	   2014).	   Additionally,	   reduced	  muscle	   strength	   in	  Myotonic	   Dystrophy	   (DM)	  and	  DMD	  patients	  lead	  to	  less	  biting	  force,	  and	  this	  has	  been	  shown	  to	  be	  involved	  in	  dentofacial	   morphology	   change	   and	   malocclusion	   by	   craniofacial	   bone	   growth	  retardation	  (Kiliaridis,	  1998).	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On	   the	   contrary,	   importance	   of	   chemical	   effects	   on	   bone	   has	   also	   been	  demonstrated.	  A	  study	  introduced	  muscle	  specific	  IGF-­‐1	  transgenic	  overexpression	  in	  mdx	  mice,	   and	   restored	  muscle	   strength	   and	   hypertrophy	   (Barton,	   2002).	   This	  suggests	  that	  local	  muscle	  IGF-­‐1	  alone	  can	  remediate	  the	  muscle	  paracrine	  function,	  which	   may	   also	   affect	   adjacent	   bone	   physiology.	   Another	   study	   showed	   IGF-­‐1	  depletion	  in	  mice	  retarded	  postnatal	  bone	  development	  and	  growth	  rate	  resulting	  in	  30%	  general	  body	  size	  reduction	  when	  compared	  with	  wild	  type	  littermates	  (Baker,	  1993).	  While	   it	   is	  now	  well	  accepted	   that	  both	  mechanical	  and	  chemical	   factors	  of	  muscle	  influence	  bone	  growth,	  morphology	  and	  density,	   it	   is	  still	  not	  clear	  to	  what	  extent	   the	   chemical	   effect	   alone	   can	   influence	   those	   properties.	   It	   is	   clinically	  significant	  to	  determine	  if	  chemical	  supplementation	  can	  overcome	  inherent	  muscle	  deficiency.	  In	  orthodontic	  patients,	  asymmetric	  facial	  skeleton	  is	  often	  the	  cause	  of	  malocclusion	   that	   requires	   skeletal	   correction,	   usually	   orthognathic	   surgery	   in	  addition	  to	  orthodontic	  treatment.	  Significant	  numbers	  of	  adult	  orthodontic	  patients	  compromise	  their	  treatment	  when	  orthognathic	  surgery	  is	  required	  because	  of	  the	  cost,	   time	   commitment	   and	   other	   existing	   or	   potential	   health	   complications.	   In	  adolescents	  and	  children,	  most	  surgery	  is	  delayed	  until	  skeletal	  growth	  is	  complete	  so	  that	  the	  outcome	  is	  more	  predictable.	  However,	   if	   the	   growth	   potential	   could	   be	  maximized	   or	   stimulated,	   while	   young	  patients	  are	  still	  in	  growth	  period,	  surgery	  may	  become	  unnecessary.	  	  Insulin	  like	  growth	  factor	  1	  (IGF-­‐1)	  is	  a	  single	  polypeptide	  chain	  involved	  in	  growth,	  development	  and	  metabolism	  of	  bone	  and	  muscle.	  While	  almost	  all	  cells	  in	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the	  body	  have	  IGF-­‐1	  receptors,	  and	  hence	  are	  affected	  by	  IGF-­‐1,	  it	  is	  known	  to	  play	  a	  key	  role	  in	  muscle	  hypertrophy,	  repair	  and	  strength	  (Adams	  and	  McCue	  1998).	  One	  way	   is	   to	   act	   directly	   on	   muscle	   cells	   to	   produce	   more	   protein	   synthesis	   and	  increase	  mass	  via	  PI3K-­‐Akt-­‐mTOR	  signaling	  pathway	  (Li,	  2002).	  Another	  way	  is	  IGF-­‐1	   binds	   to	   increase	   activation	   of	   satellite	   cells,	   which	   can	   re-­‐new	   themselves	   and	  replace	   the	   reservoir	   satellite	   pool	   or	   differentiate	   into	   myoblasts	   and	   form	   new	  muscle	  fiber	  (Barton,	  2010).	  	  Circulating	   IGF-­‐1	   is	   primarily	   produced	   in	   the	   liver,	   yet	   most	   tissues,	  including	   skeletal	   muscle,	   produce	   local	   IGF-­‐1	   that	   plays	   a	   paracrine	   role	   on	   any	  given	   tissue.	   It	   has	   been	   supported	   that	   bone	  physiology	   relies	   on	   both	   paracrine	  and	   endocrine	   IGF-­‐1.	   While	   muscle	   size	   and	   growth	   were	   not	   compromised	   in	  endocrine	  IGF-­‐1	  restricted	  mice,	  bone	  density	  was	  affected	  to	  be	  inferior	  to	  normal	  mice	  (Govoni,	  2007).	  Additionally,	  boosting	  circulating	  levels	  of	  IGF-­‐1	  by	  increasing	  liver	  production	  increases	  muscle	  weight,	  proposing	  that	  circulating	  IGF-­‐1	  can	  enter	  local	  tissue	  and	  have	  anabolic	  effects	  (Elis,	  2011).	  Thus,	  IGF-­‐1	  might	  act	  directly	  on	  muscle	  and	  bone,	  and	  indirectly	  on	  bone	  via	  enhancing	  muscle	  mass.	  	   So	   far,	   studies	  have	  demonstrated	   that	  muscle	  mass	  provides	   a	  mechanical	  loading	   for	   bone	   growth	   and	   strength	   in	   conjunction	   with	   local	   growth	   factors	  secreted	   by	   muscle,	   including	   IGF-­‐1.	   Discovery	   of	   the	   extent	   of	   muscle	   IGF-­‐1	  influence	   on	   muscle	   and	   bone,	   either	   by	   mechanical	   or	   chemical,	   or	   both,	   would	  benefit	   in	   orthodontic	   patients	   for	   potential	   growth	   modifications	   during	   active	  growth	   period.	   Further	   more,	   it	   is	   not	   yet	   elucidated	   if	   postnatal	  autocrine/paracrine	  IGF-­‐1	  supplemented	  at	  different	  stages	  of	  growth	  would	  affect	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Study	  Design	  	  	  	   	   MKR	  Mouse	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Age	  	  	  Muscle	  IGF-­‐1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Muscle	  Mass	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Bone	  Growth	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   	   	   	   	  	  	  	  	  	  	  	  	  ?	  
	  	  	  	  	  
	  	  	  	  	  	  	  	  
Fig.	  1	  Fig.	   1.	   In	   this	   study,	   roles	   of	   muscle	   hypertrophy	   and	   age	   on	   direct	   IGF-­‐1	   effect	   on	   bone	   are	  investigated	  using	  dominant	  IGF-­‐1	  receptor	  blocked	  (MKR)	  and	  different	  age	  mice.	  Viral	  IGF-­‐1	  (AAV-­‐IGF-­‐1)	  is	  injected	  into	  one	  side	  of	  masseter	  muscles.	  Masseter	  muscle	  fiber	  size,	  mandibular	  growth	  and	  condylar	  growth	  plate	  width	  from	  each	  experimental	  group	  are	  analyzed.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  
Specidic	  Aim	  1	  	  •  The	  effect	  of	  increased	  IGF-­‐1	  and	  masetter	  muscle	  hypertrophy	  on	  mandibular	  growth	  
Specidic	  Aim	  2	  •  The	  effect	  of	  increased	  IGF-­‐1	  on	  mandibular	  growth	  in	  the	  absence	  of	  masseter	  muscle	  hypertrophy	  
Specidic	  Aim	  3	  •  The	  effect	  of	  age	  on	  increased	  masseter	  muscle	  IGF-­‐1	  and	  mass	  alterations	  of	  mandibular	  growth	  
AAV-­‐IGF-­‐1	  Injection	  
Masseter	  muscle	  diber	  size	  
Mandibular	  length	  
Condyle	  Growth	  plate	  width	  
1.WT	  vs	  Control	  
2.WT	  vs	  MKR	  
3.	  6,	  10,	  26	  wk	  age	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Materials	  &	  Methods	  
Viral	  construction	  and	  injection	  	   A	   recombinant	   AAV	   plasmid	   (pSUB201)	  was	   constructed	   that	   contains	   the	  myosin	   light	   chain	  1/3	  promoter/enhancer,	   rat	   IGF-­‐IA	   cDNA,	   and	   simian	   virus	  40	  polyadenylation	  signal	  for	  viral	  production,	  as	  previously	  described	  (Barton,	  1998).	  Recombinant	  AAV	  serotype	  8	  (rAAV-­‐2/cap8:	  AAV-­‐2	  genomes	  pseudopackaged	  into	  AAV-­‐8	  capsids)	  was	  prepared	  by	  the	  Institute	  for	  Human	  Gene	  Therapy	  Vector	  Core	  (Philadelphia,	  PA)	  following	  published	  procedures.	  	  
Animals	  	   All	   experiments	   involving	   animals	   were	   approved	   by	   University	   of	  Pennsylvania	  Animal	  Care	   and	  Use	  Committee.	  The	   animals	  utilized	   for	   this	   study	  were	   C57Bl/6	   (WT)	  mice	   and	   the	  MKR	  mice,	  which	   harbors	   a	   dominant	   negative	  IGF-­‐I	   receptor	   transgene	   under	   the	   muscle	   creatine	   kinase	   (MCK)	   promoter	  (Fernandez,	  2001).	  Anesthetized	  WT	  mice	  of	  2	  and	  18	  weeks	  of	  age	  and	  2	  weeks	  old	  MKR	  mice	  were	  injected	  with	  AAV-­‐IGF-­‐1	  (Barton,	  1998)	  100	  μl	  of	  10%	  glycerol/PBS	  containing	   ≈1010	   rAAV	   particles	   into	   the	   interstitial	   space	   of	   the	   anterior	   muscle	  compartment	  of	  the	  right	  or	  left	  masseter.	  	   Groups	  that	  were	  injected	  at	  2	  weeks	  of	  age	  (WT	  and	  MKR)	  were	  sacrificed	  at	  two	  different	  time	  points:	  after	  4	  weeks	  (four	  WT	  and	  four	  MKR)	  and	  after	  8	  weeks	  (four	   WT	   and	   four	   MKR).	   Therefore,	   6	   and	   10	   week	   groups	   refer	   to	   the	   age	   of	  sacrifice.	  18	  weeks	  old	  mice	  group	  (WT)	  at	  the	  time	  of	  injection	  were	  sacrificed	  after	  8	  weeks,	  and	  hence	  referred	  to	  as	  26	  week	  group.	  They	  were	  divided	  into	  four	  males	  
	   9	  
and	   four	   females.	   For	   each	   group,	   control	   samples	  without	   IGF-­‐1	   treatment	  were	  sacrificed	   according	   to	   the	   strain	   (WT	   and	   MKR)	   and	   age	   matched	   experimental	  group	  (Fig.	  2).	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Fig.	  2	  Fig.	  2.	  Experimental	  groups	  of	  animals	  in	  the	  study	  are	  shown.	  Wild	  type	  (WT)	  and	  dominant	  muscle	  IGF-­‐1	   receptor	   negative	   (MKR)	   mice	   at	   6,	   10	   and	   26	   weeks	   of	   age	   were	   used.	   There	   were	   IGF-­‐1	  treated	  on	  the	  right	  side	  masseter	  (IGF-­‐1)	  and	  control	  groups.	  	  
	  
	  
WT	   6week	  
IGF-­‐1	  (n=4)	  Control	  (n=4)	  
10	  week	   IGF-­‐1	  (n=4)	  Control	  (n=4)	  
MKR	   6week	  
IGF-­‐1	  (n=4)	  Control	  (n=4)	  
10	  week	   IGF-­‐1	  (n=4)	  Control	  (n=4)	  
26	  week	  WT	  
Male	   IGF-­‐1	  (n=4)	  Control	  (n=2)	  
Female	  	   IGF-­‐1	  (n=4)	  Control	  (n=2)	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Immunohistochemistry	  of	  masseter	  muscle	  	   At	   the	   time	   of	   sacrifice,	   a	   portion	   of	   left	   and	   right	   superficial	   masseter	  muscles	  were	  harvested	  for	  evaluation	  of	  the	  fiber	  size.	  Each	  muscle	  was	  frozen	  in	  OCT	  embedding	  compound	  (Tissue	  Tek,	  Torrance,	  CA)	  in	  melting	  isopentane,	  and	  10	  µm	   cryosections	   were	   prepared.	   For	   immune-­‐staining	   procedure,	   sections	   were	  blocked	   in	   5%	  bovine	   serum	  albumin	   (BSA)/phosphate-­‐buffered	   saline	   (PBS)	   and	  incubated	  overnight	  at	  37	  °C	  in	  5%	  BSA/PBS	  containing	  a	  rabbit	  anti-­‐laminin	  (rabbit	  Ab-­‐1,	   Neomarkers,	   Fremont,	   CA).	   After	   24	   hours,	   thoroughly	   washed	   with	   PBS	  sections	   were	   incubated	   in	   5%	   BSA/PBS	   containing	   Alexa	   Fluor	   IgG	   secondary	  antibody	   (1:2,000;	   Invitrogen)	   for	  1	  hour	   in	   the	  dark	   at	   room	   temperature.	   Slides	  were	  then	  mounted	  with	  Vectashield	  DAPI	  media	  (Vector	  Laboratories,	  Burlingame,	  CA)	   and	   examined	   for	   fluorescence	   using	   a	   Leica	   DMRBE	   fluorescent	   microscope	  (Leica,	   Bannockburn,	   IL)	   equipped	   with	   a	   Micro	   Max	   digital	   camera	   (Princeton	  Instruments,	   Trenton,	   NJ)	   interfaced	   with	   Image	   Pro	   Plus	   software	   (Media	  Cybernetics,	  Bethesda,	  MD).	  Images	  were	  exported	  and	  merged	  together	  to	  make	  a	  composite	   image	   for	   each	   sample	   using	   Photoshop	   (Adobe	   Photoshop	   CC,	   2012).	  Fiber	  size	  analysis	  was	  done	  using	  in	  house	  developed	  software	  (Smith	  and	  Barton,	  2014)	  measuring	  each	  fiber	  diameter.	  	  
	  
IGF-­‐1	  content	  	   Upon	  removal	  of	  superficial	  masseter	  muscles,	  small	  portions	  of	  right	  and	  left	  deep	   masseter	   muscle	   were	   removed,	   weighed,	   and	   then	   frozen	   at	   -­‐80°C.	   IGF-­‐1	  content	   in	  muscle	  was	  evaluated	   following	  procedures	   in	   an	  ELISA	  kit	   specific	   for	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rodent	  IGF-­‐1	  (MG100,	  R&D	  Systems,	  Minneapolis,	  MN).	  IGF-­‐1	  content	  was	  calculated	  as	  ng	  IGF-­‐1	  per	  gram	  wet	  weight	  tissue	  (ng/g).	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Fig.	  3	  Fig.	   3.	   uCT	   scan	   3D	   image	   of	   craniofacial	   skeleton	   and	   mandibular	   landmarks:	   the	   most	   postero-­‐superior	  point	  of	  the	  mandibular	  condyle	  (Co),	  the	  most	  postero-­‐inferior	  point	  of	  the	  lower	  border	  of	  the	  mandible	  (Go)	  and	  the	  most	  antero-­‐inferior	  point	  at	  the	  lower	  border	  of	  the	  mandible	  (Pg).	  
	  
	  
Craniofacial	  uCT	  Imaging	  and	  Analysis	  	  	   After	   sacrifice	   and	  masseter	   tissue	   harvest,	   the	   heads	   of	   the	  wild	   type	   and	  MKR	   mice	   were	   removed	   at	   6	   and	   10	   weeks	   old.	   The	   heads	   were	   placed	   in	   4%	  paraformaldehyde	  at	  4°C	  until	  micro-­‐CT	  imaging.	  Each	  sample	  group	  was	  imaged	  by	  μCT	  (Scanco	  vivaCT	  40)	  at	  60μm	  resolution.	  	  	   Skull	   micro-­‐CT	   images	   were	   exported	   to	   image	   processing	   software	   and	  craniofacial	   dimensions	   were	   measured	   manually	   on	   micro-­‐CT	   images.	   Scanned	  images	  in	  DICOM	  format	  were	  first	  cropped	  and	  down	  sized	  using	  FIJI	  (ImageJ,	  NIH)	  and	  then	  using	  OsiriX	  (www.osirix-­‐viewer.com)	  3D	  images	  were	  constructed.	  Three	  mandible	   landmarks	  were	   identified	  on	  3D	  skull	   image	   (Fig.	  3):	   the	  most	  postero-­‐
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superior	   point	   of	   the	  mandibular	   condyle	   (Co),	   the	  most	   postero-­‐inferior	   point	   of	  the	   lower	   border	   of	   the	  mandible	   (Go)	   and	   the	  most	   antero-­‐inferior	   point	   at	   the	  lower	  border	  of	  the	  mandible	  (Pg).	  Length	  of	  mandibular	  ramus	  was	  determined	  by	  measuring	  Co	  and	  Go	  and	  the	  distance	  between	  Go	  and	  Pg	  determined	  the	  length	  of	  the	  mandibular	  corpus	  (Ramirez-­‐Yanez,	  2005).	  After	  landmarks	  were	  identified	  on	  3D	  images,	  X,	  Y	  and	  Z	  coordinates	  were	  recorded,	  then	  linear	  measurement	  values	  were	   calculated	   mathematically	   via	   Microsoft	   Excel	   software	   (Microsoft	   Corp.,	  Redmond,	  WA.).	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Fig.	  4	  Fig.	  4.	  Condyle.	  H&E	  stain.	  a,	  hypertrophic	  zone	  b,proliferating	  zone	  	  TG,	  Total	  growth	  plate	  
	  
Condylar	  growth	  plate	  analysis	  	   Additional	   histological	   analysis	   of	   decalcified	   condyle	   sections	   was	  performed	   to	  measure	   growth	   plate	   and	   hypertrophic	   zone	  widths.	   The	   heads	   of	  mice	  sacrificed	  at	  6	  week	  and	  10	  week	  were	  decalcified	  by	  leaving	  in	  10%	  EDTA	  pH	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Fiber	  diameter	  	  	   To	   evaluate	   the	   effect	   of	   IGF-­‐1	   on	  muscle	   fiber	   size,	  masseter	  muscle	   fiber	  diameter	  was	  compared	  on	  a	  small	  piece	  of	  the	  masseter	  muscles.	  For	  each	  group,	  mean	   fiber	   diameter	   of	   masseter	   muscle	   was	   calculated	   for	   comparison	   analysis.	  Muscle	   fiber	   size	   within	   the	   same	   sample	   varied	   significantly	   (Fig.	   5)	   and	   mean	  values	  from	  one	  sample	  to	  another	  showed	  high	  variance.	  	  	   For	  example,	   it	  was	  observed	   in	   control	   groups,	  6	  week	  WT	   fiber	  diameter	  was	   larger	   than	   6	   week	   MKR	   fiber	   diameter	   on	   both	   right	   side	   (62.685μm	   and	  41.185μm)	   and	   left	   side	   (57.215μm	   and	   43.6μm)	   that	  was	   statistically	   significant	  (Fig.	   6(a)).	   However,	   within	   each	   animal,	   the	   mean	   fiber	   diameter	   difference	  between	  right	  and	  left	  sides	  was	  8µm	  in	  both	  WT	  and	  MKR	  group	  (Fig.	  6(b)),	  which	  was	   approximately	   15-­‐20%	  variability	   on	   the	  mean	   fiber	   size.	   In	   6	  week	  WT	   and	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MKR	  group,	  IGF-­‐1	  treated	  group	  showed	  smaller	  fiber	  size	  than	  the	  control	  group	  on	  both	   IGF-­‐1	   treated	  and	  control	   sides.	  Further,	   in	   IGF-­‐1	   treated	  6	  week	  old	  groups,	  MKR	  mice	  had	  significantly	   larger	  mean	   fiber	  diameter	   than	  6	  week	  WT	  group	  on	  both	   IGF-­‐1	   treated	  and	  control	  sides.	  Within	  each	  group,	  no	  significant	  differences	  observed	  between	  IGF-­‐1	  treated	  (right)	  and	  control	  (left)	  sides	  in	  both	  WT	  and	  MKR	  mice	  (Fig.	  7(a)).	  	   	  	   In	   control	   groups,	   10	  week	  MKR	  mice	   showed	   smaller	   fiber	   diameter	   than	  WT,	   but	   not	   significantly.	   In	   IGF-­‐1	   treated	   groups,	   no	   significant	   differences	  were	  noted	   in	  mean	   fiber	  size	  between	  MKR	  and	  WT	   for	  both	   IGF-­‐1	   treated	   (right)	  and	  control	  (left)	  sides	  (Fig.	  7(b)).	  	   In	   26	   week	   of	   age	   group,	   there	   was	   no	   significantly	   different	   fiber	   size	  between	  control	  and	  IGF-­‐1	  treated	  groups	  for	  both	  male	  and	  female.	  Also,	  there	  was	  no	  significant	  difference	  in	  fiber	  diameters	  within	  individual	  sample	  of	  right	  and	  left.	  	  Taken	  together,	  while	  previous	  studies	  were	  able	  to	  detect	  changes	  in	  muscle	  mass	  after	   viral	   IGF-­‐1	   injection,	   the	   inherent	   variability	   in	   fiber	   size	   prevented	   us	   from	  making	  a	  meaningful	  measurement	  of	  fiber	  size	  in	  this	  study.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (a)	   	   	   	   	   	  	  (b)	  Fig.	  5	  Fig.	  5.	  (a)	  WT	  (b)	  MKR	  muscle	  fibers	  in	  anti-­‐laminin	  stain.	  Fiber	  size	  discrepancy	  within	  the	  sample	  is	  high.	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  (a)	   	   	  	  	   	   	   	  	  	  	  (b)	  	   	   	   	   	   Fig.	  6	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  Fig.	  6.	   (a)	  WT	  fiber	  diameter	  was	   larger	  than	  MKR	  (n=4)	   in	  6	  week	  control	  (n=4)	  groups.	  (b)	  Fiber	  size	  difference	  between	  right	  and	  left	  sides	  were	  about	  8µm	  in	  both	  WT	  and	  MKR.	  	  	  	  	  	  
	   	  	   	   	  	  	  	  	  	  	  	  (a)	   	   	   	   	   	  	  	  	  	  (b)	  	   	   	   	   	   Fig.	  7	  Fig.	   7.	   (a)	   6	   week	   MKR	   (n=4)	   fiber	   diameter	   was	   increased	   more	   than	   WT	   (n=4)	   with	   IGF-­‐1	  supplement.	  No	  significant	  difference	  between	  IGF-­‐1	  treated	  (Right)	  and	  control	  (Left)	  sides	  within	  the	   group.	   (b)	   10	   week	   group	   showed	   no	   significant	   difference	   with	   IGF-­‐1	   supplement	   either	  between	  WT	  and	  MKR	  or	  IGF-­‐1	  treated	  (Right)	  and	  control	  (Left)	  sides	  within	  the	  group.	  	  	  
Craniofacial	  uCT	  Image	  and	  Analysis	  	   To	   determine	   effect	   of	   IGF-­‐1	   on	   skeletal	   bone	   tissue,	   mandibular	   lengths	  were	  compared	  between	  control	  and	  IGF-­‐1	  treatment	  groups.	  Further,	  direct	  effect	  of	   IGF-­‐1	  on	  mandible	  without	  masseter	  muscle	  mass	   increase	  was	  evaluated	  using	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MKR	  and	  WT	  mice.	  All	  measurements	  from	  3-­‐4	  mice	  per	  experimental	  group	  were	  averaged	  and	  used	  the	  mean	  values	  for	  comparison	  analysis.	  Unfortunately,	  skeletal	  analysis	  in	  26	  week	  age	  group	  of	  mice	  could	  not	  be	  determined	  in	  this	  study.	  	  Mandibular	  body	  length	  (Go-­‐Pg):	  	   In	  the	  6	  week	  WT	  group,	  IGF-­‐1	  treated	  side	  (right)	  increased	  significantly	  in	  mandibular	  length	  when	  compared	  to	  untreated	  (left)	  side,	  whereas	  in	  6	  week	  MKR	  mice,	  there	  was	  only	  7%	  increase	  on	  the	  IGF-­‐1	  treated	  side	  (Fig.	  8(a)).	  Also,	  on	  IGF-­‐1	  treated	  side,	  there	  was	  a	  significant	  increase	  in	  WT	  group	  when	  compared	  to	  MKR	  group.	  In	  10	  week	  WT	  and	  MKR	  groups,	  there	  was	  no	  significant	  difference	  in	  IGF-­‐1	  treated	  (right)	  and	  untreated	  (left)	  side	  (Fig.	  8(b)).	  	  	  
	  	   	  	  	  	  	  	  	  	  (a)	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  (b)	  Fig.	  8	  Fig.	  8.	  (a)Mandibular	  length	  (Go-­‐Pg)	  increased	  in	  6	  week	  group	  on	  IGF-­‐1	  treated	  (Rigth)	  side	  in	  WT	  (n=4)	  but	  not	  significantly	  in	  MKR	  (n=4).	  (b)Mandibular	  length	  (Go-­‐Pg)	  increase	  in	  10	  weeks	  is	  not	  significant	  on	  both	  IGF-­‐1	  treated	  (right)	  and	  control	  (left)	  side	  of	  WT	  (n=4)	  and	  MKR	  (n=4).	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  (a)	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  (b)	  Fig.	  9	  Fig.	   9.	   (a)	   Ramus	   height	   (Co-­‐Go)	   increased	   with	   IGF-­‐1	   supplement	   (Right)	   in	   6	   week	   MKR	   (n=4)	  group	  but	  not	  in	  WT	  (n=4).	  (B)	  Ramus	  height	  (Co-­‐Go)	  in	  10	  week	  group	  (n=4)	  showed	  no	  difference	  between	  IGF-­‐1	  treated	  (Right)	  and	  control	  (Left)	  in	  both	  WT	  (n=4)	  and	  MKR	  (n=4).	  	  	  Mandibular	  ramus	  height	  (Co-­‐Go):	  	   In	   the	   6	   week	   MKR	   IGF-­‐1	   treated	   group,	   IGF-­‐1	   injected	   (right)	   side	   was	  significantly	   increased	  by	  17%	   in	   comparison	   to	   the	   control	   (left)	   side	   (Fig.	   9(a)),	  but	  there	  was	  no	  significant	  increase	  in	  6	  week	  WT	  on	  IGF-­‐1	  treated	  side.	  Within	  the	  10	  week	  WT	  group,	  IGF-­‐1	  treated	  side	  showed	  slight	  increase	  but	  not	  significantly.	  10	  week	  MKR	  group,	  no	  difference	  was	  observed	  between	  IGF-­‐1	  treated	  and	  control	  sides	  (Fig.	  9(b)).	  	  Taken	   together,	   IGF-­‐I	   treatment	   altered	  mandibular	   length	   in	  WT	   animals,	  and	   less	   so	   in	   MKR	   animals;	   further,	   IGF-­‐1	   treatment	   altered	   mandibular	   ramus	  height	  only	  in	  6	  week	  old	  MKR	  mice.	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Condylar	  growth	  plate	  Analysis	  	   To	   determine	   the	   effects	   of	   IGF-­‐1	   on	   maturation	   stage	   of	   the	   condyle,	  condylar	  growth	  plate	  widths	  were	  measured	   from	  right	  and	   left	  condyles	  of	  each	  sample.	  	  	  	   Total	  growth	  plate	  width	  in	  both	  WT	  and	  MKR	  mice	  was	  dependent	  on	  age.	  There	  was	  a	  significant	  total	  growth	  plate	  width	  reduction	  in	  10	  week	  WT	  and	  MKR	  group	   in	   comparison	   to	   6	   week	   comparable	   groups	   (Fig.	   10(a)).	   There	   was	   22%	  reduction	  of	  total	  growth	  plate	  in	  10	  week	  WT	  group	  when	  compared	  to	  6	  week	  WT	  group	  and	  16%	  in	  MKR	  groups.	  A	  similar	  trend	  was	  observed	  for	  both	  treated	  and	  control	  sides.	  	  	   Within	  the	  same	  group,	  although	  it	  was	  small,	   total	  growth	  plate	  width	  was	  smaller	  on	   IGF-­‐1	   treated	  side	   than	  control	   side	   in	  6	  week	  WT,	  by	  4%.	  However,	  6	  week	   MKR	   group	   showed	   no	   significant	   difference	   between	   control	   and	   treated	  sides	   of	   total	   growth	   plate	   width.	   Similarly,	   both	   10	   week	   WT	   and	   MKR	   groups	  exhibited	  no	  significant	  difference	  of	  total	  growth	  plate	  between	  right	  and	  left.	  	  	   On	  IGF-­‐1	  treated	  sides	  (right),	  hypertrophic	  zone	  width	  was	  increased	  in	  10	  week	   group	   than	   6	   week,	   in	   both	   WT	   and	   MKR	   groups	   (Fig.	   10(b)).	   There	   was	  significant	   difference	   in	   hypertrophic	   zone	   widths	   when	   comparison	   was	   made	  between	  WT	   and	   MKR.	   Both	   in	   6	   week	   and	   10	   week	   groups,	   MKR	  mice	   showed	  reduced	  hypertrophic	  zone	  width	  than	  WT	  mice	  (Fig.	  10(b)).	  The	  control	  (left)	  side	  values	  were	  very	  close	  to	  the	  right	  side’s	  and	  showed	  the	  comparable	  results.	  	  	   Both	  WT	  and	  MKR	  10	  week	  mice	  showed	  significantly	  less	  total	  growth	  plate	  width	  but	  increased	  hypertrophic	  width	  than	  6	  week	  on	  IGF-­‐1	  treated	  side	  (Fig.	  11)	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and	  control	  side.	  Taken	  together,	  the	  effects	  of	  age	  and	  mouse	  strain	  on	  the	  condylar	  growth	  plate	  were	  most	  evident,	  and	  the	  potential	  differences	  associated	  with	  IGF-­‐1	  treatment	  were	  only	  observed	  in	  the	  6	  week	  WT	  groups.	  	  	  	  	  
	   	  	   	   	  	  	  	  	  	  (a)	   	   	   	   	   	   	  	  	  	  	  	  	  (b)	  	  Fig.	  10	  Fig.	  10.	  Total	  growth	  plate	  width	  and	  relative	  hypertrophic	  width	  comparison	  on	  IGF-­‐1	  treated	  (right)	  side.	  (a)	  With	  the	  same	  groups,	  total	  growth	  plate	  width	  was	  significantly	  decrease	  in	  10	  weeks	  old	  mice	  (n=4)	  than	  in	  6	  weeks	  old	  mice	  (n=4)	  both	  in	  MKR	  and	  WT.	  (b)	  Hypertrophic	  zone	  width	  was	  increased	  in	  10	  weeks	  old	  mice	  (n=4)	  when	  compared	  to	  6	  weeks	  old	  mice	  (n=4)	  both	  in	  MKR	  and	  WT.	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Fig.	  11	  Fig.	  11.	  Comparison	  of	  mean	  total	  growth	  plate	  width	  and	  relative	  mean	  hypertrophic	  zone	  width	  in	  6	  week	  and	  10	  week	  WT	  and	  MKR	  mice.	  	  Total	  growth	  plate	  width	  was	  reduced	  in	  10	  week	  both	  WT	  and	  MKR	  mice	  and	  hypertrophic	  zone	  width	  was	  decreased	  in	  10	  week	  WT	  and	  MKR	  mice.	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Discussion	  	   The	   insulin-­‐like	  growth	   factors	   (IGFs)	  are	  a	   family	  of	   low	  molecular	  weight	  peptides	   that	   resemble	   insulin	   both	   in	   their	   structure	   and	   in	   their	   effects.	   Studies	  have	   shown	   IGFs	   regulate	   skeletal	   muscle	   growth	   and	   differentiation,	   and	  participate	  in	  attached	  bone	  physiology.	  In	  the	  orofacial	  area,	  likewise	  its	  effects	  on	  hind	   limb	   muscle	   and	   long	   bone	   the	   IGF	   system	   is	   involved	   in	   the	   growth	   and	  development	   of	   mastication	   muscle	   and	   craniofacial	   bone.	   Previous	   study	   shows	  lack	   of	   IGF-­‐1	   in	  masseter	  muscle	   decreases	   its	  muscle	  mass	   and	   disproportionate	  development	   of	   craniofacial	   skeleton	   (McAlarney,	   2001).	   In	   this	   study,	   effects	   of	  local	   IGF-­‐1	   supplement	   on	   masseter	   muscle	   and	  mandibular	   growth	   is	   evaluated	  and	   further,	   suggests	  direct	  paracrine	   role	  of	  muscle	   IGF-­‐1	  on	  bone	  growth.	   IGF-­‐1	  effects	  appear	  to	  be	  confined	  to	  active	  growth	  period	  and	  not	  in	  mature	  tissue.	  
Fiber	  diameter	  	   Reduced	  myofiber	  size	  noted	  in	  control	  groups	  of	  6	  week	  MKR	  in	  comparison	  to	  WT	  on	  both	  right	  and	  left	  sides	  (Fig.	  6(a))	  seems	  in	  agreement	  with	  the	  premise	  that	  MKR	  mice	  demonstrate	  reduced	  skeletal	  muscle	  growth	  in	  comparison	  to	  wild	  type	   (Fernandez,	   2002),	   (Kim,	   2005).	   However,	  within	   each	   control	   animal,	  mean	  fiber	  diameter	  difference	  between	  right	  and	   left	  was	  about	  15%	  of	   the	  mean	   fiber	  diameter	  in	  masseter	  muscle	  in	  both	  WT	  and	  MKR	  mice	  (Fig.	  6(b)).	  	  	   In	  10	  weeks	  old	  mice,	  however,	  there	  was	  no	  significant	  difference	  between	  WT	  and	  MKR	  controls	  and	  further,	  IGF-­‐1	  addition	  did	  not	  produce	  significant	  effect	  on	   fiber	   sizes	   in	   either	   WT	   or	   MKR	   mice	   (Fig.	   7(b)).	   It	   is	   possible	   that	   as	   mice	  become	  more	  mature	  in	  developmental	  stage,	  compensatory	  mechanism	  may	  have	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restored	  reduced	  muscle	  size	   in	  MKR	  mice,	   thus	  diminishing	  the	  difference	  to	  WT.	  Supporting	   that	  notion,	   in	  26	  week	  old	  WT	  mice	  did	  not	   show	  any	  anabolic	   IGF-­‐1	  effect	   on	  muscle	   size.	   This	   proportional	   difference	   is	   significantly	   larger	   than	   the	  differences	   observed	   between	   treated	   and	   control	   masseter	   muscle	   mass	  comparison	   in	   previous	   study,	   and	   it	   suggests	   fiber	   diameter	   difference	   does	   not	  correlate	  IGF-­‐1	  effect	  on	  muscle	  hypertrophy,	  or	  that	  a	  small	  sample	  of	  the	  masseter	  is	   not	   representative	   of	   the	   entire	   composition.	   In	   transgenic	   animals	   with	   IGF-­‐1	  manipulation	   the	  masseter	   exhibits	   10-­‐15%	   changes	   in	   fiber	   size,	  when	   sampling	  the	   entire	   muscle.	   In	   this	   case,	   we	   used	   some	   of	   the	   muscle	   for	   sectioning,	   and	  another	  part	   of	   IGF	   content.	   Thus,	   the	  native	   variability	   in	   fiber	   size	   compounded	  with	   the	  potential	   variability	   of	   the	   effects	   in	   IGF	  delivery	   suggests	   that	   obtaining	  meaningful	  data	  from	  these	  samples	  is	  impossible	  with	  our	  current	  N.	  	  	  	   However,	  another	  important	  fact	  that	  emerged	  was	  that	  effects	  were	  seen	  at	  6	  weeks	  but	  lost	  at	  10	  weeks	  of	  age.	  This	  transient	  pattern	  of	  IGF-­‐1	  effect	  confined	  to	  early	   in	  development	  was	  also	   seen	  across	  bone	  growth	  comparisons.	  Mandibular	  length	  difference	  between	  IGF-­‐treated	  and	  control	  was	  significant	  in	  6	  week	  group	  but	   not	   in	   10	   week	   group.	   Fernandez	   et	   al.	   also	   noted	   in	   a	   previous	   study	   that	  muscle	  mass	  decrease	  was	   less	   in	  adulthood	   than	  between	  0-­‐3	  weeks	  of	  mice	  age	  (Fernandez,	   2002).	   One	   interesting	   result	   from	   fiber	   diameter	   comparison	   is	   the	  increased	   diameter	   in	   6	   week	   MKR	   than	   in	   WT	   when	   muscle	   specific	   IGF-­‐1	   was	  exogenously	  added	  (Fig.	  7	  (a)),	  because	  previous	  studies	  showed	  muscle	   fiber	  size	  in	   MKR	   mice	   did	   not	   change	   with	   IGF-­‐1	   receptors	   blocked	   (Kim,	   2005).	   Further	  more,	  while	   IGF-­‐1	  delivery	  was	  only	  on	   the	   right	  masseter	  muscle,	  both	   right	   and	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left	  masseter	  myofiber	  sizes	  were	  increased.	  These	  data,	  however,	  are	  unlikely	  to	  be	  a	  valid	  indicator	  of	  IGF-­‐1	  effect	  on	  masseter	  muscle	  fiber	  size,	  due	  to	  high	  variability	  within	   the	   masseter	   muscle	   fibers	   mentioned	   previously.	   Lack	   of	   consistent	  relationship	   between	   fiber	   size	   and	   IGF-­‐1	   effects	   presented	   in	   this	   study	   again	  suggest	   that	   diameter	  measurement	  may	  be	   an	   accurate	   representation	  of	  muscle	  fiber	   size.	   Instead,	   muscle	   fiber	   cross	   sectional	   area	   compared	   in	   previous	   study	  showed	  that	  there	  is	  a	  decrease	  in	  fiber	  cross	  section,	  but	  no	  significant	  reduction	  in	  myofiber	   diameter	   of	   skeletal	   muscle	   in	   MKR	   mice	   (Fernandez,	   2002).	   Another	  possibility	  is	  that	  masseter	  muscle	  comprises	  a	  number	  of	  different	  types	  of	  muscle	  fibers,	   and	   their	   shapes	   and	   size	   differences	   are	   substantial	   (Fig.	   5).	   It	   is	   also	  apparent	   in	   control	   animals	  with	   large	   intrinsic	   variance	   in	   fiber	   size	   even	  within	  the	   same	   individual	   (Fig.	   6(b)).	   So	   far,	   in	   previous	   studies	   hind	   limb	  muscle	   fiber	  size	  has	  been	  shown	  to	  be	  affected	  by	  IGF-­‐1.	  Here,	  we	  show	  muscle	  size	  analysis	  in	  masseter	  muscle	  may	   be	  more	   complex	   than	   limb	  muscle	   and	   difficult	   to	   analyze	  just	  by	  measuring	  fiber	  diameter	  because	  of	  different	  muscle	  fiber	  composition	  and	  functions.	  	  
	  
Craniofacial	  uCT	  Image	  and	  Analysis	  	   By	  measuring	  the	  skull	   landmarks	  directly	  on	  micro	  CT	  scanned	  3D	  images,	  mandibular	   lengths	   were	   compared	   in	   two	   aspects:	   mandibular	   length	   (Pg-­‐Go)	  showing	   sagittal	   growth	   and	   ramus	   height	   (Co-­‐Go)	   that	   indicates	   vertical	   growth.	  These	  are	  the	  most	  crucial	  areas	  of	  interest	  in	  orthodontic	  treatment	  when	  skeletal	  component	  is	  included	  in	  treatment	  plan.	  The	  overall	  trend	  was	  that	  on	  injected	  side	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there	  was	  more	  growth	  both	  in	  mandibular	  length	  and	  ramus	  height.	  Regardless	  of	  IGF-­‐1	  receptors	  blocked	  or	  not,	  there	  was	  an	  increased	  growth	  in	  IGF-­‐1	  treated	  side	  when	  compared	  to	  the	  control	  side.	  Based	  on	  the	  data	  from	  the	  previous	  study	  that	  MKR	   mice	   muscle	   mass	   does	   not	   increase	   with	   IGF-­‐1	   supplement,	   this	   result	  suggests	   that	   there	   is	   a	   direct	   IGF-­‐1	   effect	   on	   mandibular	   bone	   growth	   without	  mechanical	  loading	  from	  increased	  muscle	  mass.	  IGF-­‐1	  increased	  sagittal	  growth	  of	  mandible	   in	  6	  week	   is	   shown	  by	   increase	   in	  Go-­‐Pg	   length	   (Fig.	   8(a)),	  more	   in	  WT	  than	  MKR,	   and	  more	  on	   the	   IGF-­‐1	   treated	   side	   than	   control	   side.	  This	  may	   reflect	  that	  sagittal	  growth	  is	  more	  affected	  by	  muscle	  strength	  and	  loading	  than	  chemical	  effect	  of	  IGF-­‐1.	  In	  6	  weeks	  old	  mice,	  MKR	  group	  on	  IGF-­‐1	  injected	  side	  showed	  more	  vertical	  growth	  than	  WT	  (Fig.	  9(a))	   that	  may	   indicate	  vertical	  growth	   is	  promoted	  by	   IGF-­‐1	   chemical	   effect	   acting	   directly	   on	   the	   bone.	   Studies	   have	   shown	   vertical	  growth	   of	  mandible	   is	   more	   likely	   to	   be	   affected	   by	  masticatory	  muscle	   strength	  (Sciote,	  2012)	  and	  muscle	  loading	  inhibits	  growth	  of	  condyle	  (Von	  den	  Hoff,	  2008).	  These	   support	   our	   data	   that	   reduced	   muscle	   loading	   in	   MKR	   increased	   vertical	  growth	  of	  mandible	  and	   local	   IGF-­‐1	   input	  even	  more,	  surpassing	  the	  matched	  WT.	  Both	   mandibular	   length	   and	   ramus	   height	   differences	   via	   IGF-­‐1	   addition	   became	  unnoticeable	   in	  10	  week	  group	  (Fig.	  8(b)	  and	  Fig.	  9(b)),	  probably	  due	   to	  a	  similar	  reason	  as	  the	  transient	  fiber	  size	  changes	  mentioned	  above.	  Overall,	  IGF-­‐1	  effect	  on	  bone	   growth	   together	   with	   mechanical	   strength	   from	   masseter	   muscle	   is	  multifactorial	  because	  while	  IGF-­‐1	  promotes	  growth	  on	  condyle,	  muscle	  loading	  via	  increase	  in	  muscle	  strength	  and	  mass	  will	  inhibit	  condylar	  growth.	  	  	  
Condylar	  growth	  plate	  analysis	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   The	   growth	   plate	   reflects	   longitudinal	   growth	   results	   from	   chondrocyte	  proliferation	   and	  differentiation.	   Longitudinal	   growth	   rates	   are	   high	  during	   active	  growth	  –during	  the	  first	  year	  of	   life	  and	  growth	  spurt	  (puberty)	  in	  humans,	  and	  at	  the	  end	  of	  puberty,	  growth	  plates	  fuse,	  thereby	  ceasing	  longitudinal	  growth.	  IGF-­‐1,	  together	   with	   other	   hormones	   and	   growth	   factors,	   is	   now	   considered	   as	   an	  important	  regulator	  of	  chondrocyte	  proliferation	  and	  differentiation.	  	   In	  the	  results	  shown,	  it	  was	  clearly	  demonstrated	  that	  older	  mice	  (10	  week)	  showed	  reduced	  total	  growth	  plate	  width	  than	  younger	  (6	  week)	  mice	  as	  expected	  from	  mature	  growth	  plate	   fusion.	  Further	  more,	   IGF-­‐1	  effect	  on	   total	  growth	  plate	  width	   reduction	   suggests	   that	   IGF-­‐1	   promoted	   growth	   on	   bone	   and	   exhibit	  more	  mature	   stage	   of	   growth,	   as	   less	   growth	   plate	   width	   is	   observed	   in	   mature	   bone.	  Another	   distinguishing	   feature	   from	   growth	   plate	   histology	  was	   the	   hypertrophic	  zone	   that	   was	   increased	   relative	   to	   total	   growth	   plate	   in	   older	   mice	   group.	   This	  indicates	   that	   as	   bone	   growth	   matures,	   hypertrophic	   zone	   width	   increases	   in	  relation	  to	  decreasing	  total	  growth	  plate	  width.	  There	  was	  a	  significant	  difference	  in	  hypertrophic	  zone	  width	  observed	  between	  WT	  and	  MKR.	  WT	  mice	  showed	  a	  larger	  proportion	  of	  hypertrophic	  zone	  than	  MKR	  in	  both	  6	  week	  and	  10	  week	  groups.	  This	  could	   imply	   that	   in	   WT	   mice	   mechanical	   loading	   induced	   IGF-­‐1	   production,	   and	  hence	  more	  increase	  in	  hypertrophic	  zone	  width	  than	  in	  MKR,	  which	  is	  in	  agreement	  with	   the	   previous	   thought	   IGF-­‐1	   promotes	   bone	   growth	   to	   show	   a	   more	   mature	  stage	   of	   growth	   plate.	   There	   have	   been	   debates	   on	   IGF-­‐1	   in	   chondrocytes.	  Interestingly,	   IGF-­‐1	   null	   mice	   show	   a	   30%	   decrease	   in	   linear	   dimension	   of	   the	  terminal	  hypertrophic	  chondrocytes,	  suggesting	  a	  role	  for	  IGF-­‐1	  in	  the	  regulation	  of	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chondrocyte	   hypertrophy	   but	   not	   in	   proliferation	   (Wang,	   1999).	   From	   these	  findings,	   Le	   Roith	   et	   al.	   proposed	   IGF-­‐I	   was	   responsible	   for	   chondrocyte	  differentiation	   and	   IGF-­‐II,	   controlled	   by	   GH,	   was	   involved	   in	   the	   regulation	   of	  chondrocyte	  proliferation	  (Le	  Roith,	  2001).	  Yet,	  another	  study	  in	  rats	  found	  IGF-­‐1	  in	  all	  zones	  of	  the	  growth	  plate,	  with	  the	  highest	  expression	  levels	  in	  the	  proliferating	  and	  the	  pre-­‐hypertrophic	  zones	  of	  chondrocytes	  (Reinecke,	  2000).	  Hence,	  from	  this	  study,	   it	  was	  shown	   that	   IGF-­‐1	  was	   involved	   to	   induce	  more	  mature	   form	  of	  bone	  histology,	   yet	   it	   is	   not	   clear	   whether	   IGF-­‐1	   affects	   proliferating	   or	   differentiating	  stages	  of	  chondrocytes	  development.	  	  	  	  
Conclusion	  	   From	   this	   study,	   exogenous	   local	   IGF-­‐1	  effect	  on	  muscle	  hypertrophy	  could	  not	  be	  clearly	  determined	  because	  of	  inherent	  high	  myofiber	  diameter	  discrepancy	  in	   masseter	   muscle.	   However,	   paracrine	   role	   of	   muscle	   IGF-­‐1	   directly	   on	  surrounding	   bone	   is	   demonstrated	   by	   an	   increase	   in	  mandibular	   vertical	   growth,	  while	   indirect	   IGF-­‐1	   effect	   via	  muscle	   loading	   increased	   horizontal	   growth.	   Age	   is	  shown	  to	  be	  an	  important	  factor	  to	  consider	  for	  effective	  IGF-­‐1	  anabolic	  influence	  in	  skeletal	   muscle	   fiber.	   Future	   studies	   should	   be	   directed	   towards	   potential	   direct	  IGF-­‐1	  on	  bone	  growth	  by	  evaluating	  the	  older	  mice	  mandibular	  growth	  based	  on	  the	  primary	  premise	  that	  IGF-­‐1	  is	  most	  likely	  to	  be	  effective	  only	  in	  early	  stage	  of	  post-­‐natal	  development	  from	  this	  study.	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